MBX Biosciences, Inc./$MBX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About MBX Biosciences, Inc.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
- Ticker
- $MBX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 63
- Headquarters
- Carmel, United States
- Website
- mbxbio.com
MBX Metrics
BasicAdvanced
$2.7B
-
-$2.41
-
-
Price and volume
Market cap
$2.7B
52-week high
$72.64
52-week low
$20.21
Average daily volume
566K
Financial strength
Current ratio
18.084
Quick ratio
17.82
Long term debt to equity
0.007
Total debt to equity
0.008
Profitability
EBITDA (TTM)
-117.664
Management effectiveness
Return on assets (TTM)
-22.08%
Return on equity (TTM)
-33.17%
Valuation
Price to book
6.52
Price to tangible book (TTM)
6.52
Price to free cash flow (TTM)
-28.435
Free cash flow yield (TTM)
-3.52%
Free cash flow per share (TTM)
-1.965
Growth
Earnings per share change (TTM)
-16.49%
What the Analysts think about MBX
Analyst ratings (Buy, Hold, Sell) for MBX Biosciences, Inc. stock.
Analyst projections of the future price of MBX Biosciences, Inc. stock.
Bulls say / Bears say
Canvuparatide showed a durable Phase 2 signal: 57% of evaluable patients remained responders after a year, and MBX reported sustained calcium control and no new safety signals. The once-weekly profile could ease treatment compared with daily therapy. (MBX Biosciences)
The pivotal Phase 3 trial has begun, with the first patient dosed in August. That moves the lead programme beyond Phase 2 and puts it on a defined registration path. (SEC)
MBX has nominated two further obesity candidates, MBX 5765 and MBX 6180, alongside its Phase 1 MBX 4291 programme. If its long-acting peptide approach translates into clinical benefit, this pipeline could offer upside beyond hypoparathyroidism. (SEC)
Canvuparatide’s pivotal efficacy is not established: Phase 2 enrolled only 64 patients, and its 63% responder rate versus 31% on placebo at week 12 still needs confirmation against the longer Phase 3 endpoint. (MBX Biosciences, SEC)
The obesity weight-loss signal is preliminary: the reported 7% mean loss came from a blinded eight-person Phase 1 cohort that included two placebo participants. It is not yet clear whether MBX 4291 can deliver competitive, sustained weight loss with acceptable tolerability. (SEC)
MBX has no product revenue and its second-quarter net loss widened to $37.1 million from $19.4 million a year earlier. Continued spending and reliance on equity funding—including an available $250 million share-sale facility—could dilute existing holders. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
MBX Financial Performance
Revenues and expenses
MBX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing MBX
Fund name | Fund size | $MBX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.17% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.17% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.06% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.06% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.